Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278540 | 0.87 | NR1H2 (0.52) | NR1H2NR1H3DHODHMAPTNPSR1 | |
| SCHEMBL3279253 | 0.83 | NR1H2 (0.51) | NR1H2NR1H3DHODHMAPTADORA1 | |
| SCHEMBL3279768 | 0.82 | NR1H2 (0.43) | NR1H2NR1H3HSD17B1HSD17B2MAPT | |
| SCHEMBL3278906 | 0.81 | NR1H2 (0.72) | NR1H2NR1H3 | |
| SCHEMBL35232 | 0.80 | NR1H2 (0.61) | NR1H2NR1H3HSD17B1HSD17B2ADORA1 | |
| SCHEMBL3278573 | 0.79 | DHODH (0.46) | NR1H2NR1H3DHODHMAPTNPSR1 | |
| SCHEMBL3285054 | 0.79 | CNR1 (0.55) | NR1H2NR1H3MAPTNPSR1 | |
| SCHEMBL3279134 | 0.77 | NR1H2 (0.44) | NR1H2NR1H3DHODH | |
| SCHEMBL5506808 | 0.77 | NR1H2 (0.45) | NR1H2NR1H3DHODHMAPTNPSR1 | |
| SCHEMBL3280134 | 0.75 | NR1H2 (0.64) | NR1H2NR1H3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700595-B2 | such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) | WYETH LLC (US) | 2010-04-20 | — | — | US | claimed |
| CN-101166730-A | Cinnoline compounds and their use as liver X receptor modilators | WYETH CORP (US) | 2008-04-23 | — | — | CN | claimed |
| EP-1853566-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODULATORS | Wyeth (US) | 2007-11-14 | — | — | EP | claimed |
| WO-2006094034-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODILATORS | WYETH (US) | 2006-09-08 | — | — | WO | claimed |
| US-7700595-B2 | such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| CN-101166730-A | Cinnoline compounds and their use as liver X receptor modilators | WYETH CORP (US) | 2008-04-23 | — | — | CN | disclosed |
| EP-1853566-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODULATORS | Wyeth (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060252757-A1 | Cinnoline compounds | WYETH | 2006-11-09 | — | — | US | disclosed |
| WO-2006094034-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODILATORS | WYETH (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252757-A1 | Cinnoline compounds | NR1H3, NR1H2, CNR1 | NR1H2 2/4885NR1H3 1/4885DHODH 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.